Company Presentation

Scandion Oncology develops first-in-class bio-modulating medicines to treat drug-resistant cancers. Its lead asset, SCO-101, has yielded positive data in clinical phase I and II trials.

SCO-101 has a unique dual-targeting mechanism of action, selectively targeting the protein ABCG2 and the enzyme UGT1A1 simultaneously. The aim is to maximize therapeutic efficacy while minimizing the risk of resistance development.

Scandion, from Copenhagen, is listed on Nasdaq Sweden (SCOL)